Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Iterum Therapeutics plcITRM · Entity 72802 | Chief Medical Officer | December 01, 2023 | December 04, 2023 |
| Tessera Defense & Homeland Security Inc.PHGE · Entity 8384 | Chief Medical Officer | March 30, 2021 | April 01, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Iterum Therapeutics plc
Report date December 01, 2023 · Filed December 04, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 10,369 |
Ending reported balance
After 2023-12-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-12-01 · Grant · Acquired 8,333 · Balance 13,302 F1: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split. F2: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Row 2 · 2023-12-01 · Tax withholding · Disposed 2,933 · Balance 10,369 F3: Represents the ordinary shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted RSUs. |
| Restricted Share UnitsSEC Table II · derivative / convertible security | Direct | 16,666 |
Reported balance
After 2023-12-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-12-01 · Exercise / conversion · Disposed 8,333 · Balance 16,666 F2: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F4: The number of RSUs reported on this Form 4 have been adjusted to reflect the Reverse Share Split. F5: On December 1, 2021, the reporting person was granted an award of 33,333 RSUs, 25% of which vested on December 1, 2022, with a further 25% having vested on December 1, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.
F2: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.
F3: Represents the ordinary shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted RSUs.
F4: The number of RSUs reported on this Form 4 have been adjusted to reflect the Reverse Share Split.
F5: On December 1, 2021, the reporting person was granted an award of 33,333 RSUs, 25% of which vested on December 1, 2022, with a further 25% having vested on December 1, 2023.
Tessera Defense & Homeland Security Inc.
Report date March 30, 2021 · Filed April 01, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock Options - Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $7.02 · Expires 2031-03-30 | Direct | 71,250 |
Reported balance
After 2021-03-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-03-30 · Grant · Acquired 71,250 · Balance 71,250 F1: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years. |
Filing footnotes · ownership attribution and instrument terms
F1: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 01, 2023 Filed Dec 4, 2023 22:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057258 · doc4.xml · derivative · entry 3 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,666 Underlying: Ordinary Shares · 8,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F4 · shares: The number of RSUs reported on this Form 4 have been adjusted to reflect the Reverse Share Split. F5 · derivative.exercise_date: On December 1, 2021, the reporting person was granted an award of 33,333 RSUs, 25% of which vested on December 1, 2022, with a further 25% having vested on December 1, 2023. F5 · derivative.expiration_date: On December 1, 2021, the reporting person was granted an award of 33,333 RSUs, 25% of which vested on December 1, 2022, with a further 25% having vested on December 1, 2023. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 22:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Tax withholdingOrdinary Shares | 2,933 | $2.12 | $6,217.96 |
DisclosureSEC source: 0001209191-23-057258 · doc4.xml · nonDerivative · entry 2 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,369 F3 · shares: Represents the ordinary shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted RSUs. Read SEC document |
| December 01, 2023 Filed Dec 4, 2023 22:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantOrdinary Shares | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-057258 · doc4.xml · nonDerivative · entry 1 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,302 F1 · shares: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split. F2 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 00:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022421 · doc4.xml · derivative · entry 1 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Ordinary Shares · 75,000 shares Expires 2033-03-30 F1 · derivative.exercise_date: The shares underlying this option shall vest at a rate of 33.3% of the total number of shares on the one-year anniversary of March 31, 2023 and the remaining 66.7% will vest in equal monthly installments thereafter until March 31, 2026, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date. Read SEC document |
| December 02, 2022 Filed Dec 5, 2022 22:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | SaleOrdinary Shares | 3,365 | $1.32 | $4,441.80 |
DisclosureSEC source: 0001209191-22-059733 · doc4.xml · nonDerivative · entry 2 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,969 F3 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the RSUs. This sale does not represent a discretionary trade by the reporting person. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | Exercise / conversionRestricted Share Units · Derivative | 8,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059733 · doc4.xml · derivative · entry 3 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,999 Underlying: Ordinary Shares · 8,334 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. F4 · shares: The number of RSUs reported on this Form 4 have been adjusted to reflect the Reverse Share Split. F5 · derivative.exercise_date: On December 1, 2021, the reporting person was granted an award of 33,333 RSUs, 25% of which vested on December 1, 2022. F5 · derivative.expiration_date: On December 1, 2021, the reporting person was granted an award of 33,333 RSUs, 25% of which vested on December 1, 2022. Read SEC document |
| December 01, 2022 Filed Dec 5, 2022 22:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantOrdinary Shares | 8,334 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-059733 · doc4.xml · nonDerivative · entry 1 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,334 F1 · shares: On August 17, 2022, the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported on this Form 4 have been adjusted to reflect the Reverse Share Split F2 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 22:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantRestricted Share Units · Derivative | 500,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-069494 · doc4.xml · derivative · entry 2 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Ordinary Shares · 500,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU. F3 · derivative.exercise_date: Subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date and the other terms and conditions of the Issuer's 2021 Inducement Equity Incentive Plan, the RSUs shall vest over four years with 25% of the RSUs vesting on each one-year anniversary of December 1, 2021, such that the total number of RSUs shall be fully vested by December 1, 2025. F3 · derivative.expiration_date: Subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date and the other terms and conditions of the Issuer's 2021 Inducement Equity Incentive Plan, the RSUs shall vest over four years with 25% of the RSUs vesting on each one-year anniversary of December 1, 2021, such that the total number of RSUs shall be fully vested by December 1, 2025. Read SEC document |
| December 10, 2021 Filed Dec 14, 2021 22:00 UTC | Iterum Therapeutics plc ITRM · Entity 72802 | GrantShare Option (Right to Buy) · Derivative | 1,800,000 | $0.00 Strike: $0.48 | $0.00 |
DisclosureSEC source: 0001209191-21-069494 · doc4.xml · derivative · entry 1 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,800,000 Underlying: Ordinary Shares · 1,800,000 shares Expires 2031-12-09 F1 · derivative.exercise_date: The shares underlying this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of December 1, 2021 and the remaining 75% will vest in equal monthly installments thereafter until December 1, 2025, subject to the Reporting Person providing continuous service to the Issuer on each relevant vesting date. Read SEC document |
| March 30, 2021 Filed Apr 1, 2021 20:42 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - Right to Buy · Derivative | 71,250 | $0.00 Strike: $7.02 | $0.00 |
DisclosureSEC source: 0001213900-21-019700 · ownership.xml · derivative · entry 1 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,250 Underlying: Common Stock · 71,250 shares Expires 2031-03-30 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 30, 2022, and the remainder vesting in 12 equal quarterly installments over three years. Read SEC document |
| March 25, 2020 Filed Mar 27, 2020 20:00 UTC | Tessera Defense & Homeland Security Inc. PHGE · Entity 8384 | GrantCommon Stock Options - Right to Buy · Derivative | 67,500 | $0.00 Strike: $6.21 | $0.00 |
DisclosureSEC source: 0001213900-20-007663 · ownership.xml · derivative · entry 1 Puttagunta Sailaja · CIK 0001792314 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 67,500 Underlying: Common Stock · 67,500 shares Expires 2030-03-25 F1 · derivative.exercise_date: The options vest and become exercisable over four years, with 25% of the shares subject to the option vesting on March 25, 2021, and the remainder vesting in 12 equal quarterly installments over three years. F2 · balance_after: Does not include 263,576 additional options previously granted to the Reporting Person which have different exercise prices and which vest on different schedules. F3 · ownership.nature: The options are held by SPB Consulting LLC. The Reporting Person is the sole member of SPB Consulting LLC and may be deemed the indirect beneficial owner of the securities held by SPB Consulting LLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.